Inogen (INGN)
(Delayed Data from NSDQ)
$8.48 USD
+0.17 (2.05%)
Updated Dec 20, 2024 04:00 PM ET
After-Market: $8.48 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
INGN 8.48 +0.17(2.05%)
Will INGN be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for INGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INGN
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen
5 Medical Device Stocks That Survived the 2024 Market Volatility
INGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inogen (INGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up
Inogen (INGN) Reports Q3 Earnings: What Key Metrics Have to Say
Other News for INGN
Inogen Breaks Below 200-Day Moving Average - Notable for INGN
Notable Two Hundred Day Moving Average Cross - INGN
Inogen, Inc. 2024 Q3 - Results - Earnings Call Presentation
Inogen, Inc. (INGN) Q3 2024 Earnings Call Transcript
Needham Keeps Their Hold Rating on Inogen (INGN)